Modality-specific survival outcomes of biomarker-matched therapy in unresected non-small cell lung cancer: a clinicogenomic cohort study

Jiantong Sun, Zhenyu Yang, Yin Ku, Mao Liu, Dongsheng Wu, Shiyou Wei, Lunxu Liu · 2026

Read Modality-specific survival outcomes of biomarker-matched therapy in unresected non-small cell lung cancer: a clinicogenomic cohort study by Jiantong Sun, Zhenyu Yang, Yin Ku, Mao Liu, Dongsheng Wu, Shiyou Wei, Lunxu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13557887.txt.

Description

Jiantong Sun and six colleagues used a large clinicogenomic dataset in 2026 to separate the survival effects of the two kinds of biomarker-matched therapy in lung cancer that cannot be removed surgically. Matched care means targeted pills for patients with the right mutation, or immune checkpoint drugs for patients whose tumour profile suits them. Nearly two thousand patients from the Memorial Sloan Kettering real-world dataset were analysed with weighted survival models.

Patients who received any matched therapy lived longer than those who did not, with the strongest gain in stage IV disease. Splitting the modalities changed the picture: targeted therapy linked clearly to longer survival in its eligible group, while checkpoint drugs showed no survival advantage in theirs. Sensitivity checks mostly agreed, though analyses that handle timing differently softened the matched therapy effect. The authors urge care in crediting immune drugs from records alone.

Catalog record

CREATORJiantong Sun, Zhenyu Yang, Yin Ku, Mao Liu, Dongsheng Wu, Shiyou Wei, Lunxu Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34166
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13557887

Browse the full library · About the Tower of Babel